Monographie - Etoposide

Ostatnia aktualizacja :
19/11/2024

Etoposide

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eposin	Afryka Południowa, Belgia, KolumbiaKolumbia, Malezja, Norwegia, Szwecja, Wielka Brytania
Etocris	Argentyna, Chile, Peru
Etolon	Indie
Etomedac	Luksemburg, Niemcy
Etonolver	Wenezuela
Etoposide	Francja , Grecja, Holandia
Etosid	Egipt, Indie, Malezja
Eunades	Brazylia
Euvaxon	Argentyna
Exitop	Finlandia, Niemcy, Szwecja
Fytosid	Egipt, Indie, Malezja
Lastet	Egipt, Iran, Polska, Turcja, Węgry, Włochy, Zjednoczone Emiraty Arabskie
Onkoposid	Niemcy
Riboposid	Niemcy
Sedol	Peru
Toposin	Holandia
Tosuben	Meksyk
Vepesid	Afryka Południowa, Arabia Saudyjska, Australia, Austria, Belgia, Chorwacja, Dania, Egipt, Finlandia, Grecja, Hiszpania, Holandia, Irlandia, Kanada, KolumbiaKolumbia, Luksemburg, Niemcy, Polska, Stany Zjednoczone Ameryki, Szwajcaria, Słowenia, Turcja, Węgry, Włochy
Vepeside	Maroko, Tunisie

Bibliografia : Etoposide

	typ	publikacja
3	Czasopismo	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	Czasopismo	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Czasopismo	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Czasopismo	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Czasopismo	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Czasopismo	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Czasopismo	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
140	Czasopismo	Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993 ; 50: 1405-1409.
150	Czasopismo	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Czasopismo	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
161	Czasopismo	Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY. Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. Am J Hosp Pharm 1994 ; 51: 2706-2709.
169	Czasopismo	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Czasopismo	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
184	Czasopismo	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Czasopismo	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Czasopismo	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Czasopismo	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Czasopismo	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Czasopismo	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Czasopismo	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Czasopismo	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
417	Czasopismo	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
482	Czasopismo	Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenter Sci Technol 1991 ; 45: 108-112.
491	Czasopismo	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Czasopismo	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
504	Czasopismo	Hamon M, Plas-Remoissenet D, Kubab-Alajati S. Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26). Sci Tech Pharm 1987 ; 3: 33-40.
643	Czasopismo	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
905	Czasopismo	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	Czasopismo	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033	Czasopismo	Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999 ; 56: 985-989.
1423	Czasopismo	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Czasopismo	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratorium	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1613	Czasopismo	Lepage R, Walker SE, Godin J. Stability and compatibility of etoposide in normal saline. Can J Hosp Pharm 2000 ; 53: 338-345.
1722	Czasopismo	Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J. Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions. EJHP 2002 ; 2: 33-40.
1730	Czasopismo	Björkman S, Roth B. Chemical compatibility of mitoxantrone and etoposide (VP-16). Act Pharm Nord 1991 ; 3: 251.
1819	Czasopismo	Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M. Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution. J Clin Pharm Ther 2002 ; 27: 139-142.
1895	Czasopismo	Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J. Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing. J Pharm Biomed Anal 2004 ; 35: 57-64.
1984	Czasopismo	Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J. Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions. Am J Health-Syst Pharm 2005 ; 62: 182-188.
2108	Czasopismo	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2167	Czasopismo	Joel SP, Clark PI, Slevin ML. Stability of the iv and oral formulations of etoposide in solution. Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124.
3574	Laboratorium	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3670	Czasopismo	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4024	plakat	Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P. Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique. SFPO Congress 2017 - Nantes 2017
4125	Czasopismo	D'Huart E, Vigneron J, Lider P, Demoré B. Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags. EJHP 2020 ; 27, 1: 43-48.
4304	Czasopismo	Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A. Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs R D 2014 ; 14:13?23.
4352	Czasopismo	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.
4369	Czasopismo	Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I. Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate J Pharm Biomed Anal 2020 ;178:112896

Mentions Légales